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3,3-Disubstituted oxindole derivatives bearing a nitrogen atom at the C-3 position have been synthesized 
starting from 3-alkyl oxindole through a metal free pathway. These derivatives have been tested in five human 
tumor cell lines (PC3, MCF7, SW620, MiaPaca2 and A375) and on primary cells (PBMCs) from healthy 
donors providing compound 6d showing a strong anticancer effect in all cancer lines on the low micromolar 
range. 




The oxindole is a scaffold of a large family of natural and unnatural compounds endowed with biological 
activities.1-5 Among them 3,3-disubstituted oxindole derivatives are recognized as valuable compounds for 
drug discovery,6-9 and also as key intermediates for the synthesis of many kinds of drug candidates.7,10-15 In 
particular, oxindoles bearing an amino group at the 3-position are belonging to a variety of pharmacological 
active molecules, such as the gastrin/CCK-B receptor antagonist AG-041R (1),16 the vasopressin VIb receptor 













Due to the interest of this class of oxindole derivatives, a lot of attention has been devoted to the 
development of new synthetic strategies to access to oxindoles bearing a nitrogen atom at the C-3 position.22-
24 In this field, significant advances have been achieved in the organocatalytic25-29 or metal-catalyzed30,31 α-
amination of 2-oxindoles. 
Herein, based on our experience in the functionalization of oxindole derivatives32-34 and in the 
transformation of heterocyclic rings,35-38 we describe the synthesis of a new class of 3,3-disubstituted 
oxindoles, bearing a nitrogen substituent in C-3 exploiting a metal free pathway. Continuing our researches 
in the synthesis of anticancer compounds,39-49 the aim was to investigate the potential biological activity of 
the target compounds on different cancer cell lines. 
Starting from 3-alkyl oxindoles, the 3-bromo derivatives 4 were obtained in quantitative yield by reaction 
with bromine in dichloromethane at r.t., following a procedure previously described by our group.37 
Subsequently, compounds 4 were reacted with sodium azide to form the 3-azido derivatives 5, which were 
then treated with triphenylphosphine to provide the stable iminophosphoranes 6 (Scheme 1). The compounds 
6a and 6c were quantitatively deprotected at the position 1 under basic conditions to give the corresponding 
derivatives 6f and 6g (Scheme 1). The synthesis of the target isocyanates 7 was achieved by reacting the 
iminophosphoranes 6 with CO2, in a close vessel, at 50 °C in THF. Compounds 7a, 7b, 7d and 7e were 
obtained in moderate to good yields (55-70 %). Low solubility of compounds 6f and 6g in THF, drove us to 
use as solvents DMF for 6f and MeOH for 6g. In these solvents, the reaction of 6f and 6g with CO2 provided 
the amine 8f and the amide 9 correspondingly (Scheme 1). The iminophosphorane 6c resulted unreactive 









Scheme 1. Reagents and conditions: (a) NaN3, tetrahexylammonium iodide, DCM/H2O, r.t., overnight; (b) PPh3 DEE, r.t., 3 h; 






Treatment of the azide 5d with a solution of HBr in AcOH, allowed the formation of the amine 8d, which 
was subsequently reacted with benzoyl chloride and diethyl chlorophosphate to provide compounds 10a and 







Scheme 2. Reagents and conditions: (a) HBr in AcOH, AcOH, 0 ˚C, 2 h; (b) PhCOCl or ClP(=O)(OEt)2, Et3N, DCM, 25 °C, 3 h. 
 
The synthesized compounds 6d, 7a-e, 8d, 8f, 9, 10a, 10b having the 3-aminooxindole core were tested for 
their antiproliferative activity on five human tumor cell lines, the PC3 (prostatic adenocarcinoma), the MCF7 
(breast adenocarcinoma), the SW620 (colorectal adenocarcinoma), the MiaPaca2 (pancreatic 
adenocarcinoma) and A375 (melanoma) cell lines at 50, 25, 12.5 and 6.25 M (Figures S1-S5) concentrations 
and expressed as IC50 values (Table 1). Moreover, the toxicity of the compounds on PBMCs (Peripheral 
Blood Mononuclear Cells) from healthy donors was also tested at 100, 50, 25, 12.5 and 6.25 µM 
concentrations and expressed as IC50 values (Table 1, Figure S6). 
In a preliminary evaluation some of the tested compounds showed a detectable activity (Table 1). In 
particular, the most cytotoxic derivatives in all the considered tumor cell lines were compound 6d, 
characterized by a N=PPh3 substituent linked to the C-3 position and H in position 1 and compound 7d 
characterized by a NCO substituent linked to the C-3 position and H in position 1 (Scheme 1). They showed 
an IC50 on the low micromolar range of respectively 6-10 and 7-20 M in all the considered cancer cell lines 
inducing a 100% of mortality at almost all the tested doses (Figures S1-S5).  
Other compounds such as 7a, 7b and 7e exhibited cytotoxic dose dependent effects only on prostatic cancer 
cell line PC3 (Figure S1) and 7a and 7b also on breast cancer cell line MCF7 (Figure S2) at an IC50 lower 
than 50 M (Table 1). Compounds 8d, 8f, 9 and 10a exerted toxic effects on cancer cell lines (Figures S1-
S5) but only at high concentrations with an IC50 higher than 50 M (Table 1). Compound 10b showed an 
antitumoral efficacy in adenocarcinoma cancer cell SW620 and pancreatic cell line MiaPaca2 in a dose 











PC3 MCF7 SW620 MiaPaca2 A375 PBMC 
6d 8.63 < 6.25 < 6.25 < 6.25 9.04 30.71 
7a 18.20 14.38 > 50 47.01 > 50 45.52 
7b 17.04 30.44 > 50 > 50 > 50 > 100 
7d 8.95 17.68 9.81 7.46 6.41 75.30 
7e 32.51 > 50 > 50 > 50 > 50 > 100 
8d > 50 > 50 > 50 > 50 > 50 > 100 
8f > 50 > 50 37.05 43.09 > 50 > 100 
9 N.D.b > 50 > 50 N.D.b > 50 > 100 
10a > 50 > 50 > 50 > 50 > 50 > 100 
10b > 50 > 50 27.70 30.21 > 50 51.78 
aValues of at least two independent experiments. 
b N.D. = Not Determined. 
 
The evaluation test on the toxicity in the primary cells PBMC showed that among the compounds that 
exerted an antitumor activity, compound 6d showed an IC50 of 30.71 M but with an anticancer activity at 
doses lower than 6.25 M (Table 1). Compound 7d showed an IC50 on PBMCs higher than 50 µM and 
compound 7a showed an IC50 of 45.5 µM (Table 1). 
In the present work, we have evaluated the potential anti-tumor effects of several compounds on a panel 
of stabilized human cancer cell lines. Among the compounds tested, ten of them exerted anti-cancer activity, 
although at high concentrations (in the µM range) and not in all the tested cell lines. However, when 
evaluating the toxicity in primary cells, we observed that none of the compounds was toxic at the 
concentrations effective on cancer cells. 
The most promising compounds that we believe deserve further testing are the 7d and 6d. The first compound 
exhibits an important anti-cancer effect with toxicity in PBMCs at the dose of 50 and 100 M. Compound 
6d showed to be toxic on PBMCs cells already at the dose of 25 µM but it showed a strong anticancer effect 
at doses lower than 6.25 µM. 
These two compounds exhibit the same structure excepted for the group in C-3 respectively a 
triphenyliminophosphorane group in 6d and an isocyanate group in 7d. The reduced activity of the 
compounds 7a, 7b and 7e could be probably due to the presence of the acetyl group and the ethyl carboxylate 
group in position 1. Further structural and biological studies followed by SAR study are warrant for the better 
identification of the compounds with the highest anticancer activities. 
It will be also important from a translation point of view, to assess the efficacy of the most promising 
compounds on primary cancer cells, and to shed light on their mechanisms of action, via the identification of 
putative receptors and modulation of intracellular signaling pathways. 
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